You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
The company is aiming to create a suite of products that can help researchers and manufacturers engineer various genomes at scale for multiple purposes.
The process challenges claims made in certain UC Berkeley patents on the use of CRISPR-Cas9 to edit eukaryotic genomes.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Nature this week: CRISPR-Cas9 genome editing system that does not require double-strand DNA breaks, and more.
During the five-year collaboration, the partners will research disease-causing gene mutations and develop new CRISPR-based technologies for drug discovery.
A Russian researcher wants to implant gene-edited embryos into women this year, Nature News reports.
The researchers were able to engineer variants of the base editors that reduced the off-target RNA SNVs while maintaining their on-target DNA editing.
Researchers from the Broad Institute and NIH characterized a CRISPR-associated transposase that can integrate DNA into unique sites in the E. coli genome.
An analysis using UK Biobank data indicates that the CCR5-Δ32 gene mutations He Jiankui reportedly attempted to introduce into human embryos may be deleterious.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.